



March 4, 2022

PRESS RELEASE FOR IMMEDIATE USE

Dechra is pleased to announce the licensing rights of the Malaseb® brand of dermatology products in the United States with Dermcare of Australia. This partnership complements the existing Dechra dermatology by offering a well-known and trusted brand.

Mike Eldred, President of Dechra North America, stated, “The Malaseb line of dermatology products strengthens the popular Dechra dermatology product line by offering a brand that many veterinarians use and trust.”

About Dechra

Dechra’s companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our brands include Vetoryl® Capsules (trilostane), Zycortal® Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole® Coated Tablets (methimazole), the Vetivex® line of parenteral fluids, and Phycox® joint health supplements. Osurnia® (florfenicol, terbinafine, betamethasone acetate) and the TrizUltra+Keto®, MiconHex+Triz®, MalAcetic®, and oral anti-infective product lines, including Marboquin® (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, spotlight the dermatology offerings. And the recent addition of Mirataz® (mirtazapine transdermal ointment), Porus® One, and Redonyl® Ultra Feline to the portfolio supports the underserved feline market.

Contact:

Mike Eldred
President, North American Operations
Dechra Veterinary Products
Mike.Eldred@Dechra.com

Doug Hubert
Vice President, Sales and Marketing
Dechra Veterinary Products
Doug.Hubert@Dechra.com